141 related articles for article (PubMed ID: 8141715)
21. Thrombolysis after acute myocardial infarction. Who should be added to inclusion criteria?
Figueredo VM; Amidon TM; Wolfe CL
Postgrad Med; 1994 Dec; 96(8):30-4, 37-40. PubMed ID: 7991476
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
[TBL] [Abstract][Full Text] [Related]
23. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ
Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656
[TBL] [Abstract][Full Text] [Related]
24. Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators.
Califf RM; Topol EJ
Clin Cardiol; 1992 Mar; 15(3):143-4. PubMed ID: 1551260
[No Abstract] [Full Text] [Related]
25. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
26. TIMI grade flow, mortality, and the GUSTO-III trial.
Stringer KA
Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644
[TBL] [Abstract][Full Text] [Related]
27. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
29. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Lee KL; Califf RM; Simes J; Van de Werf F; Topol EJ
Ann Intern Med; 1994 May; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
[TBL] [Abstract][Full Text] [Related]
30. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Mak KH; Moliterno DJ; Granger CB; Miller DP; White HD; Wilcox RG; Califf RM; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):171-9. PubMed ID: 9207639
[TBL] [Abstract][Full Text] [Related]
31. Breaking the thrombolytic gridlock: insights from the GUSTO trial.
Topol EJ
Cleve Clin J Med; 1993; 60(6):445-7. PubMed ID: 8287504
[No Abstract] [Full Text] [Related]
32. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
[TBL] [Abstract][Full Text] [Related]
33. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
Bates ER
Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
[TBL] [Abstract][Full Text] [Related]
34. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
[TBL] [Abstract][Full Text] [Related]
35. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
[TBL] [Abstract][Full Text] [Related]
36. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
[TBL] [Abstract][Full Text] [Related]
37. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
38. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
39. "Rescue" thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction.
White HD; Cross DB; Williams BF; Norris RM; Woo KS; Hamer AW; Elliott JM; Ormiston JA
Am J Cardiol; 1995 Jan; 75(2):172-4. PubMed ID: 7810496
[No Abstract] [Full Text] [Related]
40. Does intravenous heparin or time-to-treatment/reperfusion explain differences between GUSTO and ISIS-3 results?
Anderson JL; Karagounis LA
Am J Cardiol; 1994 Nov; 74(10):1057-60. PubMed ID: 7977047
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
